Global Diabetes Drugs Market: Overview
Diabetes is a chronic disease that occurs if sufficient insulin (blood sugar regulating hormone) is not produced by the beta cells in the pancreas (an organ that lies near the stomach) or alternatively, if the insulin is produced, but the body is not effectively able to utilize it. This causes sugars to build up in the blood. The overall deaths of people with diabetes is almost double the risk of people without diabetes. Diabetes can cause a nerve damage, blindness, kidney disease, stroke, heart attack, and other serious health problems. The symptoms of diabetes include more infections than usual, sores that are slow to heal, very dry skin, feeling very tired much of the time, tingling or numbness in hands or feet, sudden vision changes, extreme hunger, unexplained weight loss, excessive thirst, and frequent urination. Diabetes is detected by a simple blood test that is used to diagnose the glucose level in the blood.
Demand for Type 2 Diabetes to Lead Global Diabetes Drugs Market
In terms of disease type, the market is segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and impaired glucose tolerance and impaired fasting glycaemia. In terms of disease type, the diabetes drugs market has been segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and impaired glucose tolerance and impaired fasting glycaemia. The research report states that the Type 2 diabetes holds a leading share in the global market due to its higher prevalence. Accelerated pace of obesity amongst urban dwellers, improving access to healthcare, and rising disposable income are all expected to make positive impact on this segment. Sedentary lifestyle characterized by poor dietary habits is expected to spike the diagnostic rate of Type 2 diabetes. Meanwhile, Type 1 diabetes is expected to be the second leading segment. Gestational diabetes and impaired glucose tolerance and impaired fasting glycaemia are projected to grow during at a steady pace as well due to changing genetics.
Hospital Pharmacies to Remain Key Distributors of Drugs
The diabetes drugs market is classified on the basis of therapy type, disease type, distribution channels, and region. Based on the therapy type, the market is divided into glucagon-like peptide-1 (GLP-1) agonist, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, sodium glucose co-transporter 2 (SGLT2) inhibitors, Insulin and others. Based on distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Out of these distribution channels, hospitals pharmacies held a leading share in the global market due to availability of trained staff to sell medicines. Analysts expect that online pharmacies are also expected to show remarkable progress in the near future due to emergence of e-commerce and growing number of tech-savvy consumers.
North America to Leading Consumer of Diabetes Drugs
Geographically, the diabetes drugs market has been segmented into 5 major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the highest revenue in 2016, due to high prevalence of diabetes in the region. Europe is anticipated to hold second large market share in 2016 owing to increasing investment in research & development and promising pipeline of diabetes drugs in Europe. Asia Pacific is expected to grow fast, owing to the increasing awareness and promotion in the region. Middle East & Africa is anticipated to grow during the forecast period due to increasing prevalence of diabetes and growing disposable income especially in Middle East countries in the region. Latin America is expected to grow during the forecast period owing to overdependence of physicians and patients on insulin.
Key companies profiled in the report include Novo Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.
Global Diabetes Drugs Market: Snapshot
This report on the Diabetes drugs market analyzes the current and future scenario of the global market. Rise in private and public funding for diabetes drugs, rising prevalence of diabetes, and favorable regulatory scenario for new drug launch are boosting the growth of the Diabetes drugs market. Increasing geriatric population across the world and rising incidence and prevalence of diabetes such as Type 2 diabetes and Type 1 diabetes are some of the factors expected to drive the growth of Diabetes drugs market during the forecast period.
The diabetes drugs market report comprises an elaborate executive summary, which includes market snapshot that provides information about various segments. It also provides information and data analysis of the global market with respect to the segments based on therapy, disease type, distribution channel and geography. A detailed qualitative analysis of drivers and restraints, opportunities and trends have been provided in the market overview section. Additionally, the section comprises Porter’s Five Forces Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the Diabetes drugs market.
Global Diabetes Drugs Market: Segmentation
Based on the therapy, the Diabetes drugs market has been segmented into 5 types, which are Glucagon-like peptide-1 (GLP-1) agonist, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, Sodium glucose co-transporter 2 (SGLT2) inhibitors, Insulin and others. . The insulin dominated the market in terms of revenue in 2016, due to its high price, and need & demand for insulin. Insulin is expected to lead the market in the forecast period, owing to the rising geriatric population and high per capita income. SGLT2 is anticipated to grow during the forecast period owing to patents and exclusivity held for the drugs of this segment by the key players. The others segment includes the combination drugs and other drug classes are anticipated to grow during the forecast period 2017 to 2025. The Glucagon-like peptide-1 (GLP-1) agonist is anticipated to grow during the forecast period owing to rising prevalence of diabetes all over the world.Dipeptidyl-peptidase-4 (DPP-4) inhibitors held second large market share in 2016, however, the segment is anticipated to fall in the growth rate during the forecast period due to patent and exclusivity expiry.
In terms of disease type, the diabetes drugs market has been segmented into type 1 diabetes, type 2 diabetes, gestational diabetes, and impaired glucose tolerance and impaired fasting glycaemia. Type 2 diabetes has accounted for highest market share due to increasing disposable income and rising prevalence of obesity. Increasing physical inactivity created demand for the diabetes drugs. Type 1 diabetes held the second large market share in 2016 owing to increasing environmental damage all over the world that is contributing to the rising prevalence of type 1 diabetes. Gestational diabetes and impaired glucose tolerance and impaired fasting glycaemia are anticipated to grow during the forecast period 2017 to 2025 due to the high prevalence of diabetes in the relatives and heredity reason.
Different types of distribution channels are present in the diabetes drugs market those are Hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies captured highest market share in 2016, owing to the availability of trained & qualified personnel and favorable reimbursement structure. The online pharmacies is estimated to register highest CAGR in the forecast period, which is attributed to the technological adaptation and acceptance of online pharmacies by population. The retail pharmacies showed the moderate market share in 2016 owing to rising geriatric population & improvements in the healthcare facilities in developing countries are anticipated to propel the popularity of retail pharmacies during the forecast period. However, uncertain reimbursement scenarios across the world are attributed to restrain the diabetes drugs market to some extent during the forecast period.
Global Diabetes Drugs Market: Regional Segmentation
Geographically, the diabetes drugs Market has been categorized into five major regions and the key countries in the respective region: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, Japan, China, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa).
Global Diabetes Drugs Market: Competitive Landscape
The report also profiles major players in the Diabetes drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Novo Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.
Diabetes Drugs Market has been segmented as given below:
Diabetes Drugs Market, by Therapy
- Glucagon-like peptide-1 (GLP-1) agonist
- Dipeptidyl-peptidase-4 (DPP-4) inhibitors
- Sodium glucose co-transporter 2 (SGLT2) inhibitors
Diabetes Drugs Market, by Disease Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Impaired Glucose Tolerance and Impaired Fasting Glycaemia
Diabetes Drugs Market, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Diabetes Drugs Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- Latin America
- Rest of Latin America